PSYCHOBIOLOGY AND TREATMENT OF MENSTRUALLY-RELATED MOOD DISORDERS

心理生物学和月经相关情绪障碍的治疗

• 批准号: 3759347
• 负责人: D R RUBINOW
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF MENTAL HEALTH
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3759347
• 关键词: alcoholic beverage consumption; electrolyte balance; endocrine pharmacology; estrogens; female; fluoxetine; gonadotropin releasing factor; hormone regulation /control mechanism; hormone therapy; human subject; human therapy evaluation; magnesium; menstrual cycle; mood disorders; neurobiology; peptide hormone analog; premenstrual syndrome; progesterone; psychobiology; psychopharmacology; reproductive system disorder chemotherapy; serotonin; vasopressins

The goals of this project are to detect and accurately describe menstrually-related mood disorders, explore their pathophysiology and response to pharmacological and environmental manipulation, and to document the relationship between reproductive endocrine change and disorders of mood as a way of further investigating the neurobiology of psychiatric illness. In the past year we have identified: 1) the ability of GnRH analogue (Lupron) to eliminate premenstrual syndrome during the second month of administration in some but not all patients; 2) the precipitation of significant mood symptoms by either estrogen or progesterone in several patients whose symptoms were successfully treated by GnRH analogue; 3) a dramatic (25-30%) decrease in global cerebral blood flow during progesterone administration compared with estrogen administration or GnRH analogue alone; 4) significant improvement in symptoms of PMS during the luteal phase in patients receiving m-CPP, a mixed serotonin agonist; 5) significantly reduced plasma vasopressin in patients with premenstrual syndrome across the menstrual cycle; 6) significant albeit subtle increased alcohol consumption across the menstrual cycle in patients with PMS compared with controls; 7) the therapeutic efficacy of fluoxetine in ten of 13 patients with PMS; 8) the absence of a difference in magnesium retention in patients with PMS compared with controls.

该项目的目标是检测和准确描述 与精神有关的情绪障碍，探索其病理生理学， 对药理学和环境操作的反应，以及 记录生殖内分泌变化与 作为进一步研究神经生物学的一种方式 精神病的症状 在过去一年，我们确定了：1） GnRH类似物（Lupron）消除经前综合征的能力 在给药的第二个月， 患者; 2）沉淀的重大情绪症状， 雌激素或孕激素在几个病人的症状， GnRH类似物成功治疗; 3）显著（25-30%）降低 孕酮给药期间的全脑血流 与雌激素或GnRH类似物单独给药相比; 4)黄体期PMS症状显著改善 在接受m-CPP（一种混合5-羟色胺激动剂）的患者中; 5） 显著降低经前期患者的血浆加压素水平， 综合征在整个月经周期; 6）显着，虽然微妙 增加患者在月经周期中的饮酒量 与对照组相比; 7）治疗效果 氟西汀在13例PMS患者中的10例; 8）缺乏一个 PMS患者镁潴留与 对照